Prothena (PRTA) Competitors $15.22 -0.79 (-4.93%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRTA vs. DYN, HCM, CPRX, AGIO, PTGX, IOVA, AMRX, LBPH, NAMS, and IDYAShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Dyne Therapeutics (DYN), HUTCHMED (HCM), Catalyst Pharmaceuticals (CPRX), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Iovance Biotherapeutics (IOVA), Amneal Pharmaceuticals (AMRX), Longboard Pharmaceuticals (LBPH), NewAmsterdam Pharma (NAMS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Dyne Therapeutics HUTCHMED Catalyst Pharmaceuticals Agios Pharmaceuticals Protagonist Therapeutics Iovance Biotherapeutics Amneal Pharmaceuticals Longboard Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Dyne Therapeutics (NASDAQ:DYN) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Is DYN or PRTA more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -98.86%. Prothena's return on equity of -24.19% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -57.46% -51.62% Prothena -98.86%-24.19%-20.59% Do institutionals and insiders believe in DYN or PRTA? 96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by insiders. Comparatively, 28.2% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer DYN or PRTA? In the previous week, Prothena had 11 more articles in the media than Dyne Therapeutics. MarketBeat recorded 17 mentions for Prothena and 6 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.98 beat Prothena's score of 0.08 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prothena 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Which has better earnings & valuation, DYN or PRTA? Prothena has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$235.94M-$3.56-6.74Prothena$133.35M6.14-$147.03M-$2.48-6.14 Does the MarketBeat Community believe in DYN or PRTA? Prothena received 574 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Dyne Therapeutics an outperform vote while only 70.42% of users gave Prothena an outperform vote. CompanyUnderperformOutperformDyne TherapeuticsOutperform Votes3373.33% Underperform Votes1226.67% ProthenaOutperform Votes60770.42% Underperform Votes25529.58% Do analysts rate DYN or PRTA? Dyne Therapeutics presently has a consensus target price of $50.42, indicating a potential upside of 110.16%. Prothena has a consensus target price of $52.29, indicating a potential upside of 243.53%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08Prothena 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more risk and volatility, DYN or PRTA? Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. SummaryProthena beats Dyne Therapeutics on 11 of the 18 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$818.97M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-6.1410.5991.3417.19Price / Sales6.14195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book1.465.104.794.78Net Income-$147.03M$151.51M$120.07M$225.60M7 Day Performance19.00%-2.14%-1.90%-1.24%1 Month Performance5.40%-3.13%11.43%3.06%1 Year Performance-59.16%11.51%30.59%16.50% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena1.6269 of 5 stars$15.22-4.9%$52.29+243.5%-58.8%$818.97M$133.35M-6.14173Analyst ForecastNews CoverageHigh Trading VolumeDYNDyne Therapeutics3.1242 of 5 stars$26.05+1.2%$50.42+93.5%+104.9%$2.65BN/A-7.23100HCMHUTCHMED2.5943 of 5 stars$14.94-4.1%$19.00+27.2%-15.0%$2.60B$838M0.001,988Positive NewsCPRXCatalyst Pharmaceuticals4.6873 of 5 stars$21.78+1.9%$31.14+43.0%+48.7%$2.60B$398.20M18.12167AGIOAgios Pharmaceuticals4.2912 of 5 stars$44.19+13.4%$56.33+27.5%+53.6%$2.52B$32.87M3.73390Analyst ForecastPTGXProtagonist Therapeutics3.582 of 5 stars$41.45+0.9%$53.78+29.7%+100.0%$2.47B$60M15.44125News CoveragePositive NewsIOVAIovance Biotherapeutics4.005 of 5 stars$7.93+1.3%$22.33+181.6%+2.8%$2.42B$1.19M-5.25500AMRXAmneal Pharmaceuticals2.8869 of 5 stars$7.75-1.0%$10.00+29.0%+47.1%$2.40B$2.68B-11.387,700Analyst DowngradeNews CoveragePositive NewsLBPHLongboard Pharmaceuticals0.6636 of 5 stars$59.98+0.0%$59.56-0.7%+986.6%$2.34BN/A-26.9020NAMSNewAmsterdam Pharma2.8425 of 5 stars$24.50-0.8%$36.20+47.8%+142.4%$2.26B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3238 of 5 stars$25.95+3.0%$53.67+106.8%-23.7%$2.24B$3.92M-10.8180Analyst Forecast Related Companies and Tools Related Companies Dyne Therapeutics Competitors HUTCHMED Competitors Catalyst Pharmaceuticals Competitors Agios Pharmaceuticals Competitors Protagonist Therapeutics Competitors Iovance Biotherapeutics Competitors Amneal Pharmaceuticals Competitors Longboard Pharmaceuticals Competitors NewAmsterdam Pharma Competitors IDEAYA Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRTA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRTA Stock Alerts